IP Library Granted Patent US 7,402,729
Granted Patent B2
US 7,402,729 · App. 11/151,227 · Granted Jul 22, 2008

Human artificial chromosome containing human antibody λ light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,729
App. No.
11/151,227
Granted
Jul 22, 2008
Kind
B2
Abstract

The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody λ light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.

Claims (14)

1. A chimeric human antibody-producing mouse, wherein the antibody-producing mouse carries (1) human artificial chromosome ΔHAC or ΔΔHAC in which a 2.5 Mb region (ΔHAC) or a 1.5 Mb region (ΔΔHAC) from human chromosome 22 containing an unrearranged human antibody λ light chain locus is linked to a human chromosome 14 fragment containing an unrearranged human antibody heavy chain locus and (2) an unrearranged human antibody κ light chain transgene retained on KCo5 that is inserted into a mouse chromosome of the human antibody-producing mouse, at least both alleles of endogenous antibody heavy chain and κ light chain are disrupted or inactivated, and a human antibody heavy chain comprising a human antibody Ig γ isotype, a human antibody κ light chain, and a human antibody λ light chain are expressed in serum;

wherein at least 85% of the cells of the human antibody-producing mouse retain the human artificial chromosome ΔHAC or ΔΔHAC.

2. The human antibody-producing mouse according to claim 1 , which carries at least 40% of the variable region of the human antibody κ light chain.

3. The human antibody-producing mouse according to claim 1 , which carries all the variable regions of the human antibody heavy chain, the human antibody κ light chain, and the human antibody λ light chain.

4. The human antibody-producing mouse according to claim 1 , wherein the human antibody κ light chain locus inserted into the mouse chromosome is derived from human chromosome 2.

5. The human antibody-producing mouse according to claim 1 , wherein the human artificial chromosome is ΔΔHAC.

6. The human antibody-producing mouse according to claim 1 , wherein the human artificial chromosome is ΔHAC.

7. The human antibody-producing mouse according to claim 1 , wherein the human artificial chromosome is ΔΔHAC and 100% of the cells of the human antibody-producing mouse retain the human artificial chromosome.

8. A method for producing an antibody, which comprises: immunizing the mouse according to claim 1 , and obtaining a polyclonal antibody from the mouse.

9. The method according to claim 8 , wherein the polyclonal antibody is obtained from the blood of the mouse.

10. A method for producing an antibody, which comprises:

immunizing the mouse according to claim 1 with a desired antigen;

producing a hybridoma by fusing a mouse myeloma cell with a B cell derived from the mouse,

identifying the hybridoma that expresses a monoclonal antibody comprising human immunoglobulin heavy chains and light chains against the antigen, and producing the monoclonal antibody.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE AND ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 022390 FRAME 0234. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 26, 2021
From: KYOWA HAKKO KOGYO CO., LTD.
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 056583/0647 →
MERGER Recorded Jun 3, 2015
From: MEDAREX, L.L.C.
To: E. R. SQUIBB & SONS, L.L.C.
Reel/Frame 035775/0436 →
MERGER Recorded May 7, 2014
From: MEDAREX, INC.
To: MEDAREX, L.L.C.
Reel/Frame 032836/0250 →
MERGER Recorded Mar 13, 2009
From: KIRIN PHARMA CO., LTD.
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 022390/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2008
From: KIRIN BEER KABUSHIKI KAISHA
To: KIRIN PHARMA KABUSHIKI KAISHA
Reel/Frame 021098/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2005
From: KUROIWA, YOSHIMI; TOMIZUKA, KAZUMA; YOSHIDA, HITOSHI; ISHIDA, ISAO
To: KIRIN BEER KABUSHIKI KAISHA; MEDAREX, INC.
Reel/Frame 017163/0033 →